Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimen

Leuk Lymphoma. 2015 Apr;56(4):1160-3. doi: 10.3109/10428194.2014.947978. Epub 2014 Oct 7.

Authors

Nuria Dominguez¹, Maria Luisa Manzano, Raquel Muñoz, Ana Martin, Inmaculada Fernandez, Gregorio Castellano

Affiliation

¹ Department of Gastroenterology, Hospital Universitario 12 De Octubre , Madrid , Spain.

PMID: 25115508
DOI: 10.3109/10428194.2014.947978

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Female
Hepatitis B / complications
Hepatitis B / virology*
Hepatitis B virus / physiology*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / complications
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Middle Aged
Rituximab / administration & dosage
Time Factors
Vidarabine / administration & dosage
Vidarabine / analogs & derivatives
Virus Activation / drug effects*

Substances

Rituximab
Vidarabine
fludarabine